anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Inguinal hernia repair is a frequently performed surgical procedure, with laparoscopic repair emerging as the preferred approach due to its lower complication rate and faster recovery compared to open repair. Mesh-based tension-free repair is the gold standard for both methods. In recent years, robotic hernia repair has been introduced as an alternative to laparoscopic repair, offering advantages such as decreased postoperative pain and improved ergonomics. This study aims to compare the short- and long-term outcomes, including the surgical stress response, postoperative complications, quality of life, and sexual function, between robotic-assisted transabdominal preperitoneal (rTAPP) and laparoscopic TAPP inguinal hernia repairs.
METHODS: This randomized controlled trial will involve 150 patients from the Surgical Department of the University Hospital of Southern Denmark, randomized to undergo either rTAPP or laparoscopic TAPP. Surgical stress will be quantified by measuring C-reactive protein (CRP) and cytokine levels. Secondary outcomes include complication rates, quality of life, sexual function, and operative times. Data analysis will adhere to the intention-to-treat principle and will be conducted once all patient data are collected, with outcomes assessed at various postoperative intervals.
DISCUSSION: This study holds significance in evaluating the potential advantages of robotic-assisted surgery in the context of inguinal hernia repairs. It is hypothesized that rTAPP will result in a lower surgical stress response and potentially lower the risk of postoperative complications compared to conventional laparoscopic TAPP. The implications of this research could influence future surgical practices and guidelines, with a focus on patient recovery and healthcare costs. The findings of this study will contribute to the ongoing discourse surrounding the utilization of robotic systems in surgery, potentially advocating for their broader implementation if the benefits are substantiated.
TRIAL REGISTRATION: ClinicalTrials.gov NCT05839587. Retrospectively registered on 28 February 2023.
Hepatocellular carcinoma (HCC) is the primary malignancy of hepatocytes and the second most common cause of cancer-related mortality across the globe. Despite significant advancements in screening, diagnosis, and treatment modalities for HCC, the mortality-to-incidence ratio remain unacceptably high. A recent study indicates that a minor population of HCCs are AFP negative or express the normal range of AFP levels. Although it is a gold standard and a more reliable biomarker in the advanced stage of HCC and poorly differentiated tumors, it does not serve as a suitable means for screening HCC. AFP plays a significant role in the development and progression of HCC and understanding its role is crucial. By examining the molecular mechanisms involved in AFP-mediated tumorigenesis, we can better understand HCC pathogenesis and identify potential therapeutic targets. This article details the role of alpha-fetoprotein (AFP) in the carcinogenic transformation of hepatocytes. The article also focuses on information about the structure, biosynthesis, and regulation of AFP at the gene level. Additionally, it discusses the immune evasion, metastasis, and control of gene expression that AFP mediates during HCC.
Patients receive tagraxofusp-erzs IV QD over 15 minutes on days 1-5. Treatment repeats every 28-42 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
The present invention relates to health care medicated spirit for nourishing the kidney and strengthening yang, which comprises the following components with the weight portions: 40 to 60 portions of hairy antler, 50 to 70 portions of goat kidney, 40 to 60 portions of turtle shell, 5 to 15 portions of tokay, 50 to 70 portions of prepared rhizome of rehmannia, 20 to 40 portions of Chinese angelica, 50 to 70 portions of ginseng, 150 to 250 portions of epimedium herb, 10 to 30 portions of common cnidium fruit, 25 to 35 portions of pipe fish, 40 to 60 portions of medicinal indianmulberry root, 20 to 40 portions of cassia bark, 50 to 70 portions of cherokee rose fruit, 50 to 70 portions of dodder seed, 50 to 70 portions of radix ophiopogonis, 20 to 40 portions of rehmannia root, 50 to 70 portions of Chinese wolfberry fruit and 8000 to 12000 portions of rice spirit. The formula contains hormone components, such as pipe fish, goat kidney, tokay, epimedium herb, common cnidium fruit, etc., so the medicinal effect is rapid. Meanwhile, the components have the functions for nourishing the kidney and strengthening yang, and are assisted by blood and qi replenishing medicine, such as hairy antler, prepared rhizome of rehmannia, Chinese angelica, ginseng, astragalus root, etc. Therefore, the health care medicated spirit has the effect for treating both the manifestations and the roots of diseases. Moreover, the formula comprises the components for cooling blood and clearing away internal fire, and the balance of yin and yang is achieved. The formula is scientific and precise, so the health care medicated spirit is capable of nourishing the kidney, strengthening yang, replenishing blood and benefiting qi. Meanwhile, the health care medicated spirit attaches importance on both cold and heat. Therefore, the medicated spirit can be used as health care medicated spirit and can be drunk for a long time, while uncomfortableness, such as desiccation, etc., can not exist.
PURPOSE: Post-hemorrhagic ventricular dilation (PHVD) leads to developmental delays in premature infants, yet the optimal timing of neurosurgical interventions is unknown. Neuroimaging modalities have emerged to delineate injury and follow the progression of PHVD. Fronto-temporal horn ratio (FTHR) is used as a marker of ventricular dilation and can be a standardized tool to direct the timing of neurosurgical intervention. Our study determined a pre-operative FTHR measurement threshold to predict short- and long-term outcomes.
METHODS: This is a retrospective cohort study of premature infants with severe intraventricular hemorrhage (IVH) who developed PHVD requiring neurosurgical intervention and were treated in a level IV NICU between 2012 and 2019. Receiver operating characteristic (ROC) curve and area under the curve (AUC) analyses were performed to evaluate the accuracy of pre-operative FTHR for predicting developmental delay. In-hospital outcomes and developmental assessments were analyzed.
RESULTS: We reviewed 121 charts of infants with IVH and identified 43 infants with PHVD who required neurosurgical intervention. We found FTHR measurements were an excellent predictor of cognitive and motor delay with an AUC of 0.89 and 0.88, respectively. An average pre-operative FTHR of ≥ 0.67 was also associated with worse lung and feeding outcomes. There was excellent inter-observer reliability of individual components of FTHR measurements.
CONCLUSIONS: Early intervention for PHVD is ideal but not always practical. Identification of ventricular size thresholds associated with better outcomes is needed to direct timing of neurosurgical intervention.
Dipeptidylpeptidase IV inhibitor (herein referred to as DPP-IV) that may be 98.5-100% pure is a high-dose drug capable of being directly compressed with specific excipients into sold form dosage forms, such as tablets and capsules having desired, hardness, disintegrating ability and acceptable dissolution characteristics. DPP-IV is not inherently compressible and thus presents formulation problems. Excipients used in the formulation enhance the flow and compaction properties of the drug and tableting mix. Optimal flow contributes to uniform die fill and weight control. The binder used ensures sufficient cohesive properties that allow DPP-IV to be compressed using the direct compression method. The tablets produced provide an acceptable  in vitro  dissolution profile.
BACKGROUND AND PURPOSE: Use of thromboprophylaxis effectively prevents pulmonary embolism (PE) and deaths after total hip and knee arthroplasty (THA and TKA). The optimum length of thromboprophylaxis is not known and has traditionally been based on the type of operation. Nowadays, a more individualized approach is preferred. This study analyzed if risk stratification-based planning of thromboprophylaxis has an association with the all-cause mortality after fast-track THA and TKA.
PATIENTS AND METHODS: We compared fast-track THAs and TKAs operated between 2015-2016 and 2020-2021. Between 2015 and 2016, all patients received a routine length of thromboprophylaxis. From 2020 onwards, thromboprophylaxis was planned by risk stratification, and patients at low risk for venous thromboembolism received thromboprophylaxis only during hospitalization. All causes of death within 90 days of surgery were identified and the incidence of mortality was calculated. Mortality rates between the two periods were then compared.
RESULTS: Between 2015 and 2016, 3192 arthroplasties were performed. A total of eight deaths occurred within 90 days of surgery, yielding an incidence of all-cause mortality of 0.3% (95% CI 0.1-0.5). Between 2020 and 2021, a total of 3713 arthroplasties were performed to patients who received risk stratification-based thromboprophylaxis. Thirteen of these patients died within 90 days of surgery, yielding an all-cause mortality incidence of 0.4% (95% CI 0.2-0.6). Cardiovascular diseases were the main cause of death during both study periods. None of the deaths were caused by PEs.
INTERPRETATION: Risk stratification-based thromboprophylaxis was not associated with increased all-cause mortality within 90 days of fast-track THA and TKA.
The invention discloses injection biogel containing tripterigium wilfordii dlycosides. The injection gel comprises tripterigium wilfordii dlycosides and biogel substrates for injection. If the biogel is used for cell culturing, a cell culturing liquid can also be added into the gel substrates. The problem that immunological rejection is resistant after the administration of Chinese medicinal tripterigium wilfordii dlycosides so as to inconveniently medicate, and particularly, the rejection resistant treatment on local transplants is not ideal are solved; by injecting the tripterigium wilfordii dlycosides biogel through a local subcutaneous injection or muscle injection manner, the medicines are slowly and locally released, and the immunological rejection effect of anti-local transplants is achieved. Through the design of the injection biogel containing the tripterigium wilfordii dlycosides, a research on immunosuppressive agents of the medicine at home and abroad can be promoted, and the biogel has a certain application value. The injection biogel is simple in principle, convenient to use and can reach scale massive production; and moreover, the injection biogel lays a foundation for development and clinical test of new medicines of the preparation.
Fecal matter solution (feces, glycerol and saline solution) will be pipetted into commercially available acid-resistant hypromellose capsules (DRCaps, Capsugel) (650 μL), which will be closed and then secondarily sealed. Capsules will be stored frozen at -80°C (-112°F). Patients will swallow 30 frozen capsules on two consecutive days.
Post-acute sequelae of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) disease (COVID-19), called as long COVID syndrome, is a major global public health issue after recovery from COVID-19. The disease occurs in symptomatic patients irrespective of illness severity. The symptoms continue after four wk of recovery from acute illness and persist beyond three months. Risk factors for long COVID include older age, female gender, multiple co-morbidities including diabetes mellitus, prior chronic respiratory illnesses, hospitalized patients with severe disease, especially receiving assisted ventilation, high viral load, reactivation of Epstein Barr (EB) virus and human herpes virus 6 (HH6), circulating auto antibodies against various organs and type I interferon. The prevalence varies from 10 to 20 per cent, and most data have been reported from high-income countries. Any system can get involved in long COVID. The symptoms include fatigue, cognition impairment, cough and dyspnoea, anosmia, hair loss and diarrhoea, among others. While there are no laboratory tests for confirmation of diagnosis, reduced complement C7 complexes at six months, and a two-gene biomarker including FYN and SARS-CoV-2 antisense ribonucleic acid (RNA) are emerging as potentially useful biomarkers for long COVID. There should be no alternative disease to explain various symptoms. Vaccination against SARS-CoV-2 and early use of oral antiviral nirmatrelvir within the first five days in patients with acute mild disease having various risk factors for progression to severe disease help in preventing long COVID. Several clinical trials are underway for the treatment of long COVID and the results of these are eagerly awaited. Physical and mental rehabilitation at home, at community level or in the hospital setting as appropriate is essential in patients with long COVID.
Patients receive pembrolizumab on day 1 of each cycle. Cycles repeat every 3 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy on day 1 of each cycle over 5 treatment fractions. All patients also receive fludeoxyglucose F-18 intravenously and fluorine F 18 florilglutamic acid IV and undergo PET/ CT during screening and on study. Patients also undergo collection of blood samples, as well as CT and MRI throughout the trial.
Available data from lactation studies indicate that oxycodone is present in breastmilk and that doses of less than 60 mg/day of the immediate-release formulation are unlikely to result in clinically relevant exposures in breastfed infants. A pharmacokinetics study utilizing opportunistic sampling of 76 lactating women receiving oxycodone immediate-release products for postpartum pain management showed that oxycodone concentrates in breastmilk with an average milk to plasma ratio of 3.2. The relative infant dose was low, approximately 1.3% of a weight-adjusted maternal dose (see Data).

In the same study, among the 70 infants exposed to oxycodone in breastmilk, no adverse events were attributed to oxycodone. However, based on known adverse effects in adults, infants should be monitored for signs of excess sedation and respiratory depression (see Clinical Considerations). There are no data on the effects of the oxycodone on milk production.

Acetaminophen is also excreted in breast milk in low concentrations.

The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for PERCOCET and any potential adverse effects on the breastfed infant from PERCOCET or from the underlying maternal condition.

Infants exposed to PERCOCET through breast milk should be monitored for excess sedation and respiratory depression. Withdrawal symptoms can occur in breastfed infants when maternal administration of an opioid analgesic is stopped, or when breast-feeding is stopped.
Chronic Venous Disease (CVD) is a widespread clinical condition with a high prevalence in the western world, affecting more than 10% in young adults and more than 70% in older individuals (age \>70 years). CVD clinical manifestations vary from mild clinical signs, including varicose veins, to more advanced and severe signs such as. Lower limb edema, skin changes, and venous leg ulceration (VLU) which impact the quality of life (QoL) of affected patients. Sexual dysfunction (SD), generally affects QoL, and specifically SD has never been evaluated in CVD patients. Clinical stages are described by the CEAP (Clinical-Etiology-Anatomy-Pathophysiology) classification that is an internationally accepted standard for describing patients with CVD. CEAP defines the following clinical classes, C0 includes no visible or palpable signs of venous disease; C1 includes telangiectasia and reticular veins; C2 includes trunk VV of variable origin; C2r includes recurrent varicose veins; C3 includes lower limbs edema; C4a includes pigmentation or eczema; C4b includes lipodermatosclerosis or atrophie blanche; C4c includes corona phlebectatica; C5 includes healed ulcer; C6 includes active ulcer; C6r includes recurrent active ulcer. Moreover, each clinical class may be subcharacterized by a subscript indicating the presence (symptomatic, s) or absence (asymptomatic, a) of symptoms attributable to venous disease, such as leg heaviness, achy or tired legs, cramping, restless legs. The most severe form of CVD is defined Chronic Venous Insufficiency (CVI) and corresponds to C3-C6 classes of CEAP. For the treatment of CVD several strategy, often combined can be used such as the administration of vasoactive drugs (VADs), or the utilization of compression devices (elastic stockings or bandages) and several surgical or endovascular techniques.

Regarding sex dysfunction there are several unidimensional self-report measures available for assessing sexual dysfunction, all of them with some advantages and limitations. One of the most scale used in this context, proved useful in several clinical contexts is the ASEX (Arizona Sexual Experience) scale that is considered extremely reliable, valid, and sensitive for measuring sexual dysfunction with optimal internal consistency. ASEX is a five-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm. Possible total scores range from 5 to 30. Generally, a subject with a total ASEX score of \> 19, any one item with a score of \> 5, or any three items with a score of \> 4 would have sexual dysfunction.

The aim of this study is to evaluate sexual functioning with ASEX scale among patients with CVD, at various clinical stages, before and after treatment.
Tinnitus distressed patients are patients who experience symptoms of anxiety or depression with tinnitus. This group will receive both 0.5 mg/kg ketamine hydrochloride in saline and placebo, saline, with Magnetic Resonance Spectroscopy scans and audiometry testing and scales.
See Table 1 for dosage recommendations for acute and maintenance treatment of bipolar I disorder in adult and pediatric patients (7 to 17 years).

Obtain serum lithium concentration assay after 3 days, drawn 12 hours after the last oral dose and regularly until patient is stabilized. Fine hand tremor, polyuria, and thirst may occur during initial therapy for the acute manic phase and may persist throughout treatment. Nausea and general discomfort may also appear during the first few days of lithium administration. These adverse reactions may subside with continued treatment, concomitant administration with food, or temporary reduction or cessation of dosage.

Each 5 mL of Lithium Oral Solution contains 8 mEq of lithium ion (Li+) which is equivalent to the amount of lithium in 300 mg of lithium carbonate. See Table 2 for lithium carbonate and lithium oral solution dose conversion.

Table 2. Lithium Carbonate and Lithium Oral Solution Dose Conversion
The patients will receive one dose of GC007F. GC007F dosage ranges from 6×10\^4 to 2×10\^6 CAR+T/Kg.
We retrospectively analyzed 18 patients who underwent SNM for urinary or bowel dysfunction between 2017 and 2022 in our clinic. We excluded 2 patients due to non-effective responses after the test period. After local ethics committee approval was obtained from our institute (Number and date: 21-12.1T/14). Patient characteristics and demographic data including age, gender, indications to the SNM, age at diagnosis, and comorbidities were collected from our Hospital patients' record system. Urinary functions were evaluated by the ICIQ-SF questionnaire form. Patients' diagnosis, implantation duration, complications, and improvement of symptoms were recorded.
NEW MATERIAL:A peptide expressed by the formula (R is C10H21 or C11H23). USE:An inhibitor against cyclic adenosine 3',5'-monophosphate phosphodiesterase (hereinafter abbreviated to PDE) having the possibility of improving the saccharide metabolism, cardiotonic action, smooth muscle relaxing action, bronchodilator action, coronary arterial vasodilator action and improving action on lipid metabolism, etc. by controlling the level of the cyclic adenosine monophosphate (hereinafter abbreviated to cAMP) in cells to inhibit the hydrolytic enzyme PDE of the cAMP and further expectable antihypertensive, antiallergic and antiasthmatic action, etc. PROCESS:A strain, e.g. Bacillus subtilis c-756 (FERM-P No. 6785), belonging to the genus Bacillus, and having the ability to produce a peptide containing acyl groups is cultivated in a general culture medium consisting of a carbon source, nitrogen source and inorganic salt to separate, collect and obtain the above- mentioned peptide containing the acryl groups.
PURPOSE: To obtain a patch type skin whitening cosmetic in a new dosage form capable of percutaneously administering a regulated amount of a skin whitening substance for a long period. CONSTITUTION: This patch for skin whitening contains a skin whitening substance having tyrosinase suppressing activities as an active ingredient. The patch for skin whitening is a matrix type composed of an exposed site protecting layer 1, a main content-containing and tacky layer 2 and an adhesion site protecting layer 6 or a storage vessel type composed of the exposed site protecting layer 2, a main content layer, a release rate regulating membrane, a tacky layer and the adhesion site protecting layer. A compound having reducing properties such as ascorbic acid and its derivative, kojic acid and its derivative, glucosamines, hydroquinone and its derivative, a compound having SH group, butylene hydroxytoluene (B.H.T.) and butylene hydroxyaniline (B.H.A.) is used as the active ingredient having the skin whitening actions.
Compsn. for treating biliary lithiasis contains as active ingredients hymecromone (I; 4-methyl-7-hydroxy-coumarin) and chenodeoxycholic acid (II), pref. 100-500mg (I) and 20-300mg (II) per unit dose. Compsn. are formulated conventionally for oral administration e.g. opt. coated tablets; hard or soft gelatin capsules; solns. or suspensions. Tablets may be coated with sugar or a polymer-based film and the soft capsules can contain (I) and (II) suspended in polyoxyethylene glycol. (II) is already known for treating gall stones but has side effects and is expensive. (I) is spasmolytic for the main bile duct and for the sphincter of Oddi (so facilitates expulsion of small calculi into the duodenum), has choleretic activity and reduces the cholesteral content of the bile. When used together tolerance is improved; the dose of (II) required as reduced, and effect is rapid.
The invention discloses a paclitaxel pharmaceutical composition and a preparation method thereof. The paclitaxel pharmaceutical composition consists of paclitaxel, a solubilizing agent, a stabilizing agent, an excipient, an acidity regulator and water for injection. A paclitaxel injection is prepared by adopting a freeze drying method. Compared with the prior art, the paclitaxel pharmaceutical composition disclosed by the invention is different in solubilizing process, solubilizing effect and stability. The composition does not contain an organic solvent, thus, the paclitaxel injection has the characteristics of simpler production process, more perfect appearance, shorter freeze drying time and lower equipment requirement. The composition does not contain polyoxyethylenated castor oil, so that the paclitaxel composition has no anaphylactic reaction or hemolysis or irritation. By detection, the paclitaxel injection prepared by adopting the composition and the preparation method disclosed by the invention is high in dissolvability and stability and is suitable for large-scale industrial production.